Targeted radiation therapy for recurrent prostate cancer using molecular imaging
Molecular Imaging Informed Radiation Dose Escalation to Sites of Recurrent Disease and De-escalation to Uninvolved Areas in Salvage Radiotherapy for Prostate Cancer
This study is testing a new way of using targeted radiation therapy for men with recurrent prostate cancer by using special imaging to focus treatment on the problem areas while protecting healthy tissue.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 80 (estimated) |
| Ages | 18 Years and up |
| Sex | Male |
| Sponsor | University Health Network, Toronto Academic / other |
| Drugs / interventions | radiation |
| Locations | 2 sites (London, Ontario and 1 other locations) |
| Trial ID | NCT05328505 on ClinicalTrials.gov |
What this trial studies
This clinical trial focuses on men with recurrent prostate cancer after radical prostatectomy, utilizing PSMA PET imaging to guide radiation therapy. Participants will receive escalated radiation doses to areas of recurrence while reducing doses to unaffected regions. The study aims to improve treatment outcomes by personalizing radiation therapy based on molecular imaging results. Follow-up will occur for up to five years to assess the effectiveness and safety of this approach.
Who should consider this trial
Good fit: Ideal candidates are men over 18 with a confirmed diagnosis of prostate adenocarcinoma who have experienced biochemical relapse after surgery.
Not a fit: Patients with distant metastasis or contraindications to radiation therapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more effective treatment of recurrent prostate cancer while minimizing side effects.
How similar studies have performed: Similar studies utilizing molecular imaging for targeted radiation therapy have shown promise, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Men older than 18 years old. * Histologically proven initial diagnosis of adenocarcinoma prostate cancer. * Previous radical prostatectomy. * Biochemical relapse with local or regional recurrence proven on PSMA PET. * Five or less positive nodes on the PSMA PET. * ECOG 0-1 Exclusion Criteria: * Presence of para-aortic lymph nodes or distant metastasis. * Chronic pelvic inflammatory disease. * Contraindication for radiation treatment. * Previous radiation treatment within the pelvis
Where this trial is running
London, Ontario and 1 other locations
- London Health Sciences Centre — London, Ontario, Canada (Recruiting)
- Princess Margaret Cancer Center — Toronto, Ontario, Canada (Recruiting)
Study contacts
- Study coordinator: Andrew McPartlin, MD
- Email: andrew.mcpartlin@uhn.ca
- Phone: 416-946-4501
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.